Recent publication showcasing our telomerized Wharton’s jelly-MSCs as EV-cell factories
April 4th, 2023, Vienna, Austria
Our telomerized Wharton’s jelly-derived MSCs (WJ-MSC/TERT273) were employed in an article recently published by Prof. Dr Kerstin Otte’s lab at the University of Applied Sciences Biberach, Germany.
The authors aimed to compare different cells, defining their respective EV characteristics and EV production capabilities for potential clinical applications. Among the cells tested (HEK293 adherent and suspension, CAP SKOV3 and CHO-K1), our WJ-MSC/TERT273-derived EVs displayed pro-angiogenic and wound healing activity confirming their regenerative capabilities.
Evercyte has an extensive portfolio of telomerized cell lines which can be grown without limitations in vitro while maintaining cell type-specific markers and functions. Additionally, newly developed cell lines established under xeno-free conditions with full documentation of any manipulation step can be employed for the production of extracellular vesicles under GMP conditions for pre-clinical applications.